We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales
Read MoreHide Full Article
Bristol-Myers Squibb Company’s (BMY - Free Report) reported a mixed fourth quarter, with earnings missing expectations while sales beating the same. Shares declined around 2% in pre-market trading.
In the past one year, Bristol-Myers’ share price was down 21%, compared unfavorably with the 4.6% decrease witnessed by the Zacks classified Large-Cap Pharma industry.
Earnings Miss
The company’s fourth-quarter 2016 earnings came in at 63 cents per share, missing the Zacks Consensus Estimate of 66 cents but increasing 66% from the year-ago period.
Total revenue of $5.24 billion was above the Zacks Consensus Estimate of $5.15 billion. Moreover, reported revenues jumped 22% from the year-ago quarter. Strong product sales drove the top line in the reported quarter.
Quarterly Details
Global revenues were up 24%, when adjusted for foreign exchange impact.
Sales in the U.S. improved 20% to $2.7 billion, while international revenues improved 25%. Adjusted for foreign exchange impact, international revenues were up 28%.
Leukemia drug Sprycel raked in sales of $494 million, up 15%. Melanoma drug Yervoy contributed $264 million to the top line during the reported quarter, up 23%.
Opdivo, which is approved for multiple cancer indications, generated revenues of $1.3 billion, higher than $920 million in the third quarter of 2016.
However, performance of key drugs in the Virology unit was disappointing. Sales of Baraclude declined 4% to $296 million. Both the Reyataz and Sustiva franchises deteriorated 24% and 21% to $206 million and $246 million, respectively.
Nevertheless, sales of Eliquis were $948 million during the reported quarter, up 57% year over year. Bristol-Myers has a partnership with Pfizer Inc. (PFE - Free Report) for Eliquis. Bristol-Myers’ HCV franchise contributed $226 million to its top line, down 51%. Orencia revenues were up 14% to $625 million.
Adjusted research and development (R&D) expenses in the quarter increased 27% to $1.4 billion while marketing, selling and administrative expenses dipped 3% to $1.5 billion.
Gross margin was 73.6% in the quarter, compared with 77.8% in the year-ago quarter, primarily due to product mix.
2016 Results
Full-year 2016 sales rose 17% to $19.43 billion, slightly above the Zacks Consensus Estimate of $19.29 billion.
Adjusted earnings for 2016 were $2.83 per share, up 41% year over year but falling short of the Zacks Consensus Estimate of $2.85. Earnings were in line with the guidance range of $2.80 to $2.90 per share.
2017 Guidance
Bristol-Myers provided its earnings guidance for 2017. The company expects earnings in the range of $2.70 to $2.90 per share. The Zacks Consensus Estimate for earnings is pegged at $2.92.
R&D expenses are expected to increase in the high-single digit range. Marketing, selling and administrative expenses are anticipated to decrease in mid- to high- single-digit range.
Bristol-Myers is transforming its operating model to focus resources on the company’s highest priorities, accelerate its pipeline and streamline the infrastructure. The company expects operating expenses to be roughly flat with 2016 levels through 2020.
Bristol-Myers Squibb Company Price and EPS Surprise
Bristol-Myers’ fourth-quarter results were mixed with the company beating on revenues but missing on earnings expectations. Nevertheless, robust sales of drugs like Opdivo, Orencia, Eliquis, Sprycel and Yervoy should continue driving top line growth. Meanwhile, we are positive on Bristol-Myers’ efforts to develop its pipeline.
Bristol-Myers carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) and Sunesis Pharmaceuticals, Inc. . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%.
Sunesis’ loss estimates narrowed 5.06% and 8.80% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales
Bristol-Myers Squibb Company’s (BMY - Free Report) reported a mixed fourth quarter, with earnings missing expectations while sales beating the same. Shares declined around 2% in pre-market trading.
In the past one year, Bristol-Myers’ share price was down 21%, compared unfavorably with the 4.6% decrease witnessed by the Zacks classified Large-Cap Pharma industry.
Earnings Miss
The company’s fourth-quarter 2016 earnings came in at 63 cents per share, missing the Zacks Consensus Estimate of 66 cents but increasing 66% from the year-ago period.
Sales Beat
Total revenue of $5.24 billion was above the Zacks Consensus Estimate of $5.15 billion. Moreover, reported revenues jumped 22% from the year-ago quarter. Strong product sales drove the top line in the reported quarter.
Quarterly Details
Global revenues were up 24%, when adjusted for foreign exchange impact.
Sales in the U.S. improved 20% to $2.7 billion, while international revenues improved 25%. Adjusted for foreign exchange impact, international revenues were up 28%.
Leukemia drug Sprycel raked in sales of $494 million, up 15%. Melanoma drug Yervoy contributed $264 million to the top line during the reported quarter, up 23%.
Opdivo, which is approved for multiple cancer indications, generated revenues of $1.3 billion, higher than $920 million in the third quarter of 2016.
However, performance of key drugs in the Virology unit was disappointing. Sales of Baraclude declined 4% to $296 million. Both the Reyataz and Sustiva franchises deteriorated 24% and 21% to $206 million and $246 million, respectively.
Nevertheless, sales of Eliquis were $948 million during the reported quarter, up 57% year over year. Bristol-Myers has a partnership with Pfizer Inc. (PFE - Free Report) for Eliquis. Bristol-Myers’ HCV franchise contributed $226 million to its top line, down 51%. Orencia revenues were up 14% to $625 million.
Adjusted research and development (R&D) expenses in the quarter increased 27% to $1.4 billion while marketing, selling and administrative expenses dipped 3% to $1.5 billion.
Gross margin was 73.6% in the quarter, compared with 77.8% in the year-ago quarter, primarily due to product mix.
2016 Results
Full-year 2016 sales rose 17% to $19.43 billion, slightly above the Zacks Consensus Estimate of $19.29 billion.
Adjusted earnings for 2016 were $2.83 per share, up 41% year over year but falling short of the Zacks Consensus Estimate of $2.85. Earnings were in line with the guidance range of $2.80 to $2.90 per share.
2017 Guidance
Bristol-Myers provided its earnings guidance for 2017. The company expects earnings in the range of $2.70 to $2.90 per share. The Zacks Consensus Estimate for earnings is pegged at $2.92.
R&D expenses are expected to increase in the high-single digit range. Marketing, selling and administrative expenses are anticipated to decrease in mid- to high- single-digit range.
Bristol-Myers is transforming its operating model to focus resources on the company’s highest priorities, accelerate its pipeline and streamline the infrastructure. The company expects operating expenses to be roughly flat with 2016 levels through 2020.
Bristol-Myers Squibb Company Price and EPS Surprise
Bristol-Myers Squibb Company Price and EPS Surprise | Bristol-Myers Squibb Company Quote
Our Take
Bristol-Myers’ fourth-quarter results were mixed with the company beating on revenues but missing on earnings expectations. Nevertheless, robust sales of drugs like Opdivo, Orencia, Eliquis, Sprycel and Yervoy should continue driving top line growth. Meanwhile, we are positive on Bristol-Myers’ efforts to develop its pipeline.
Bristol-Myers carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) and Sunesis Pharmaceuticals, Inc. . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%.
Sunesis’ loss estimates narrowed 5.06% and 8.80% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>